lifestyle.pspl.com

Author: AlzeCure Pharma

New scientific Article Published on TrkA-NAM ACD137 Against Osteoarthritic Pain

May 7, 2026
AlzeCure Publishes its Interim Report for January – March 2026

May 7, 2026
Adjusted Timeline for the Previously Communicated Rights Issue

May 6, 2026
Last Patient has Completed AlzeCure’s Phase Ib Clinical Study with NeuroRestore ACD856

May 5, 2026
AlzeCure Pharma Publishes its Annual Report for 2025

May 3, 2026
AlzeCure Pharma to Present at Redeye Healthcare Day on April 14

May 3, 2026
AlzeCure Pharma to Present at Redeye Alzheimer’s Theme Event on April 9

May 2, 2026
AlzeCure Presents New Preclinical Data with NeuroRestore ACD856 at the Alzheimer’s Conference AD/PD

May 1, 2026
AlzeCure Pharma to Present at Stora Aktiedagarna in Stockholm on March 11

April 28, 2026
AlzeCure Pharma Carries Out a Fully Secured Rights Issue of Approximately SEK 30.1 million

April 26, 2026